THE OPTIMAL DURATION OF CONSOLIDATION TREATMENT PRIOR TO CESSATION OF NUC THERAPY IN HBEAG-NEGATIVE PATIENTS

Research output: Contribution to journalJournal Article peer-review

Original languageAmerican English
JournalHepatology
Volume70
StatePublished - 2019

Cite this